Rod Raynovich's  Instablog

Rod Raynovich
Send Message
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 30 years executive experience including Abbott and JNJ and has been involved three successful start-ups. He has a B.S, from Penn State University and an MBA from... More
My company:
Raygent Capital
My blog:
raygent.com
  • Rayno Life Science Portfolio Biopharmaceuticals: ALXN, GILD, REGN, SGEN 0 comments
    Oct 4, 2012 10:49 AM | about stocks: ALXN, REGN

    Biotechnology Sector Continues Amazing Bull Run Up 40% YTD

    The Rayno Life Science Portfolio had nice gains today with 1% + moves from Biogen-Idec (NASDAQ:BIIB) and Gilead Sciences (GILD) and with our bellwether ETF (NASDAQ:IBB) eking out a 0.5% gain at its 52 week high. Since the bull market began in February 2009 several stocks on our focus list have had huge gains: Alexion 6.7X, Biogen-Idec 3.13X, Regeneron 9X and ViroPharma 2.5X.We have recently provided a list of drivers for the biotechnology sector but added that a bubble is not yet evident even though CNBC-TV is talking it up more lately.

    Today two stocks offer a reminder of volatility and speculation in the life science sector:

    • Sarepta Therapeutics (NASDAQ:SRPT) is up 185% to $42.39 on news of its experimental drug Eteplirsen for treating muscular dystrophy. The Company (formerly known as AVI BioPharma) will push for early FDA approval without Phase 3 data even though the clinical study had only 12 patients. The market cap of SRPT now exceeds $900M with 2012 sales estimates of $44M and cash of $24.5M.
    • On Tuesday shares of Arqule Inc. (NASDAQ:ARQL) plunged 56% on news that its lung tumor drug failed to meet its goals for survival rates.
     

     

    2012   Price Original P Price %Ret Price Price % Ret
    Summary   Jy'10 Recomm   Dec'10 2010 Apr'11 10/3/12 YTD  
                         
                         
    Alexion ALXN 50.45 2/2/09 35 80.6 130 100.8 117 63.7 split
    Albany Mol AMRI   2/10/11 4.68 added 4.32 3.5 20  
    Astex ASTX trade 12/27/11 1.63       3 58  
    Amgen AMGN 51.7 2/2/09 55 54.9 0 54 86.6 16  
    Biogen BIIB 49.42 2/2/09 48.5 67.1 37 73.25 152 38  
                         
    Cephalon CEPH 55.95 2/2/09 76.5 61.7 -19 76.92 80.18 30 acquired
                         
    Cubist CBST 20.7 2/2/09 21.5 21.4 -3 28.35 48.6 22.7  
    Exelixis EXEL trade 9/2/10 3.3 8.21 148 11.12 4.77 1  
    First Trust FBT 30.4 4/15/10 37.5 39.1 3 41.3 47.6 45.6  
    Gilead GILD 34.9 2/2/09 51 36.2 -29 42.81 70 71.5  
    iShares ETF IBB 76.6 2/2/09 70.5 93.4 32 101.1 145.9 40  
                         
    Micromet MITI 6.28 2/2/09 4 8.12 103 5.46 10.91 272 acquired
                         
    ImmunoGen IMGN New 12/22/11 12.4       15.2 31  
    Optimer OPTR   2/18/11 11.8 added 13.8 13 6.6  
    Regeneron REGN 21.6 2/2/09 17.5 32.8 82 45.43 157 183  
    Seattle Gen. SGEN 11.85 2/2/09 9.5 15 57 15.72 26.9 60.9  
    ViroPharma VPHM 10.88 2/2/09 12 17.3 44 20.05 30.2 0  
                         
    Paired Trade closed           JY 5 CLOSED
    Pharmacycl PCYC long 6/8/12 38.2       58.45 51  
    Medivation MDVN short 6/8/12 86.8       95.43    
                         
    XBI               95 40.6  
                         

    Disclosure: I have no positions in any stocks mentioned, but may initiate a short position in SRPT over the next 72 hours.

    Stocks: ALXN, REGN
Back To Rod Raynovich's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.